WO2007079276A3 - Magnetic nanoscale particle compositions, and therapeutic methods related thereto - Google Patents
Magnetic nanoscale particle compositions, and therapeutic methods related thereto Download PDFInfo
- Publication number
- WO2007079276A3 WO2007079276A3 PCT/US2006/060419 US2006060419W WO2007079276A3 WO 2007079276 A3 WO2007079276 A3 WO 2007079276A3 US 2006060419 W US2006060419 W US 2006060419W WO 2007079276 A3 WO2007079276 A3 WO 2007079276A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- energy
- magnetic
- methods
- bioprobes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1255—Granulates, agglomerates, microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
Abstract
Disclosed are thermotherapeutic compositions for treating disease material, and methods of targeted therapy utilizing such compositions. These compositions comprise a) stable single domain magnetic particles; b) magnetic nanoparticles comprising aggregates of superparamagnetic grains; or c) magnetic nanoparticles comprising aggregates of stable single magnetic domain crystals and superparamagnetic grains. These compositions may also comprise a radio isotope, potential radioactive isotope, chemotherapeutic agent. These methods comprise the administration to a patient's body, body part, body fluid, or tissue of bioprobes (energy susceptive materials attached to a target-specific ligand), and the application of energy to the bioprobes so as to destroy, rupture, or inactivate the target in the patient. Energy forms, such as AMF, are utilized to provide the energy. The disclosed methods may be useful in the treatment of a variety of indications, including cancers, diseases of the immune system, central nervous system and vascular system, and pathogen-borne diseases.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008539149A JP2009513722A (en) | 2005-11-01 | 2006-11-01 | Magnetic nanoscale particle composition and therapeutic method related thereto |
CA002628106A CA2628106A1 (en) | 2005-11-01 | 2006-11-01 | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
EP06849146A EP1945159A4 (en) | 2005-11-01 | 2006-11-01 | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73236805P | 2005-11-01 | 2005-11-01 | |
US11/264,680 US7731648B2 (en) | 2001-07-25 | 2005-11-01 | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US60/732,368 | 2005-11-01 | ||
US11/264,680 | 2005-11-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007079276A2 WO2007079276A2 (en) | 2007-07-12 |
WO2007079276A3 true WO2007079276A3 (en) | 2008-02-21 |
Family
ID=38228900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/060419 WO2007079276A2 (en) | 2005-11-01 | 2006-11-01 | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
Country Status (5)
Country | Link |
---|---|
US (1) | US7731648B2 (en) |
EP (1) | EP1945159A4 (en) |
JP (1) | JP2009513722A (en) |
CA (1) | CA2628106A1 (en) |
WO (1) | WO2007079276A2 (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US7951061B2 (en) | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
WO2004091394A2 (en) * | 2003-04-15 | 2004-10-28 | Philips Intellectual Property & Standards Gmbh | Method to determine the spatial distribution of magnetic particles and magnetic particle administering compositions |
JP4583372B2 (en) * | 2003-04-15 | 2010-11-17 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for improved identification of the spatial distribution of non-aggregated magnetic particles in an examination region |
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
US8118754B1 (en) | 2007-11-15 | 2012-02-21 | Flynn Edward R | Magnetic needle biopsy |
US8060179B1 (en) | 2006-11-16 | 2011-11-15 | Scientific Nanomedicine, Inc. | Biomagnetic detection and treatment of Alzheimer's Disease |
US7365289B2 (en) * | 2004-05-18 | 2008-04-29 | The United States Of America As Represented By The Department Of Health And Human Services | Production of nanostructures by curie point induction heating |
CN1733314A (en) * | 2004-08-11 | 2006-02-15 | 张阳德 | Process for preparing cerebrose albumin magnetic adriamycin nanometer particle |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US9964469B2 (en) | 2005-02-28 | 2018-05-08 | Imagion Biosystems, Inc. | Magnetic needle separation and optical monitoring |
US20100259259A1 (en) * | 2005-09-21 | 2010-10-14 | Markus Zahn | Systems and methods for tuning properties of nanoparticles |
US7744596B2 (en) * | 2005-10-13 | 2010-06-29 | Boston Scientific Scimed, Inc. | Magnetically augmented radio frequency ablation |
US20070140974A1 (en) * | 2005-12-15 | 2007-06-21 | General Electric Company | Targeted nanoparticles for magnetic resonance imaging |
US20080187487A1 (en) * | 2006-05-03 | 2008-08-07 | Gustavo Larsen | Methods for producing multilayered particles, fibers and sprays and methods for administering the same |
WO2008060393A2 (en) * | 2006-10-24 | 2008-05-22 | Iso Therapeutics Group Llc | The use of materials and external stimuli for synovectomy |
US8447379B2 (en) | 2006-11-16 | 2013-05-21 | Senior Scientific, LLC | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US8333993B1 (en) | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
EP2104468A2 (en) * | 2007-01-08 | 2009-09-30 | Gross, Yossi | In-situ filter |
AU2008206064A1 (en) * | 2007-01-19 | 2008-07-24 | Triton Biosystems, Inc. | Thermotherapy susceptors and methods of using same |
JP5313906B2 (en) * | 2007-04-12 | 2013-10-09 | インダストリー−アカデミック コーペレイション ファウンデイション, ヨンセイ ユニバーシティ | Magnetic resonance imaging agent comprising metal oxide magnetic nanoparticles containing zinc |
US9387036B2 (en) * | 2007-05-14 | 2016-07-12 | Pyrexar Medical Inc. | Apparatus and method for selectively heating a deposit in fatty tissue in a body |
US20090306646A1 (en) * | 2007-05-14 | 2009-12-10 | Bsd Medical Corporation | Apparatus and method for injection enhancement of selective heating of a deposit in tissues in a body |
EP2005973A1 (en) * | 2007-06-22 | 2008-12-24 | nanoPET Pharma GmbH | Compositions containing positron emitting inorganic particles and their use in medicine, in particular for diagnostic procedures |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
CA2695969A1 (en) | 2007-08-15 | 2009-02-19 | Yeda Research & Development Co. Ltd. | Regulators of mmp-9 and uses therof |
WO2009076465A1 (en) | 2007-12-11 | 2009-06-18 | University Of Maryland, College Park | Methods and systems for magnetic focusing of therapeutic, diagnostic or prophylactic agents to deep targets |
US8388509B2 (en) | 2007-12-11 | 2013-03-05 | Tokitae Llc | Systems, devices, and methods including paramagnetic oscillation, rotation, and translation of hemozoin asymmetric nanoparticles in response to dark-field or Rheinberg detection of the presence of hemozoin |
US8385997B2 (en) | 2007-12-11 | 2013-02-26 | Tokitae Llc | Spectroscopic detection of malaria via the eye |
KR100998569B1 (en) * | 2008-03-31 | 2010-12-07 | 한국원자력연구원 | A radioimmunoconjugate for diagnosis and treatment of cancer or metastasis and development of cancer or cancer metastasis inhibitor using thereof |
US9011913B2 (en) * | 2008-04-04 | 2015-04-21 | The Regents Of The University Of California | Use of functionalized magnetic nanoparticles in cancer detection and treatment |
CN102056563A (en) * | 2008-04-09 | 2011-05-11 | 康奈尔大学 | Nanoparticle-mediated microwave treatment methods |
US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
CN102067250B (en) * | 2008-04-16 | 2014-08-27 | 干细胞技术公司 | Magnetic particles |
US8579787B2 (en) | 2008-05-19 | 2013-11-12 | University Of Maryland College Park | Methods and systems for using therapeutic, diagnostic or prophylactic magnetic agents |
KR101101832B1 (en) | 2008-05-20 | 2012-01-05 | 연세대학교 산학협력단 | Heat Generating Nanomaterials |
US9333163B2 (en) * | 2008-10-06 | 2016-05-10 | Massachusetts Institute Of Technology | Particles with multiple functionalized surface domains |
US20130023714A1 (en) * | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
CA2745281A1 (en) * | 2008-11-14 | 2010-05-20 | Columbia University | Applying torque to paramagnetic structures in bodies using dual magnetic fields |
EP2387787B1 (en) | 2008-12-19 | 2018-09-12 | Ferronova Pty Ltd | Magnetic nanoparticles |
WO2011012735A1 (en) * | 2009-07-31 | 2011-02-03 | Universidad Del País Vasco | Copper nanoparticles with magnetic properties |
US9572695B2 (en) | 2009-08-24 | 2017-02-21 | New Phase Ltd | Phase-change and shape-change materials |
TW201114437A (en) * | 2009-10-20 | 2011-05-01 | Univ Nat Chiao Tung | Magnetic nanoparticles for magnetic resonace imaging |
WO2011050049A2 (en) * | 2009-10-21 | 2011-04-28 | The University Of North Carolina At Chapel Hill | Delivery systems for brachytherapy, and associated methods |
US8565892B2 (en) | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
JP5865252B2 (en) * | 2009-11-02 | 2016-02-17 | パルス セラピューティクス インコーポレイテッド | Magnetostatic stator system and wireless control method of magnetic rotor |
US10194825B2 (en) | 2009-11-06 | 2019-02-05 | Imagion Biosystems Inc. | Methods and apparatuses for the localization and treatment of disease such as cancer |
US9095270B2 (en) | 2009-11-06 | 2015-08-04 | Senior Scientific Llc | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US9044141B2 (en) * | 2010-02-10 | 2015-06-02 | Tokitae Llc | Systems, devices, and methods including a dark-field reflected-illumination apparatus |
US8781184B2 (en) * | 2010-02-10 | 2014-07-15 | Tokitae Llc | Systems, devices, and methods for detection of malaria |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US20110301401A1 (en) * | 2010-06-08 | 2011-12-08 | Larson Andrew C | Compositions and methods for thermoradiotherapy |
DE102010050644A1 (en) * | 2010-11-09 | 2012-05-10 | Studiengesellschaft Kohle Mbh | Process for the preparation of carbon-protected superparamagnetic or magnetic nanospheres |
US20120197063A1 (en) * | 2011-01-31 | 2012-08-02 | Rainer Meinke | Systems and Methods Which Remove Material From Blood Vessel Walls |
US8197471B1 (en) * | 2011-02-14 | 2012-06-12 | Samuel Harry Tersigni | Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease |
WO2012121528A2 (en) * | 2011-03-04 | 2012-09-13 | Samsung Life Public Welfare Foundation | Magnetic nanocomposite specific for thyroid cancer and use thereof |
US20120283503A1 (en) * | 2011-04-29 | 2012-11-08 | The Johns Hopkins University | Nanoparticle loaded stem cells and their use in mri guided hyperthermia |
US10773095B2 (en) * | 2011-06-21 | 2020-09-15 | Lockheed Martin Corporation | Direct magnetic imaging with metamaterial for focusing and thermal ablation using SPION nanoparticles for cancer diagnosis and treatment |
WO2013020701A2 (en) | 2011-08-10 | 2013-02-14 | Magforce Ag | Agglomerating magnetic alkoxysilane-coated nanoparticles |
US9005151B2 (en) | 2011-09-07 | 2015-04-14 | Choon Kee Lee | Thermal apparatus |
ES2671622T3 (en) | 2011-12-21 | 2018-06-07 | Iso Therapeutics Group Llc | Compositions and radioactive methods for therapeutic use |
GB2514714A (en) * | 2012-03-29 | 2014-12-03 | Spiration Inc | Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue |
US9883878B2 (en) | 2012-05-15 | 2018-02-06 | Pulse Therapeutics, Inc. | Magnetic-based systems and methods for manipulation of magnetic particles |
JP2015521054A (en) | 2012-06-05 | 2015-07-27 | カプリコール,インコーポレイテッド | Optimized methods for generating cardiac stem cells from heart tissue and their use in cardiac therapy |
WO2014028493A2 (en) | 2012-08-13 | 2014-02-20 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
KR101409296B1 (en) | 2012-09-07 | 2014-06-24 | 서울대학교산학협력단 | Method of selective activation for magnetic nanoparticle and selectively activated magnetic nanoparticle |
KR101868675B1 (en) * | 2012-10-05 | 2018-06-18 | 연세대학교 산학협력단 | Compositions for Hyperthermia Therapy comprising Sensitizing Material |
US9895549B2 (en) | 2012-11-06 | 2018-02-20 | The Florida International University Board Of Trustees | On-demand drug release using magneto-electric nanoparticles |
WO2014074584A1 (en) * | 2012-11-06 | 2014-05-15 | Sakhrat Khizroev | On-demand drug release using magneto-electric nanoparticles |
WO2014085651A1 (en) * | 2012-11-29 | 2014-06-05 | The Johns Hopkins University | A process for making iron oxide nanoparticle preparations for cancer hyperthermia |
US9409148B2 (en) | 2013-08-08 | 2016-08-09 | Uchicago Argonne, Llc | Compositions and methods for direct capture of organic materials from process streams |
US20150092811A1 (en) * | 2013-09-24 | 2015-04-02 | Worcester Polytechnic Institute | Nanoparticles-Based Taggant Systems and Methods |
GB201412040D0 (en) * | 2014-07-07 | 2014-08-20 | Nottingham University Hospitals Nhs Trust | Magnetic resonance imaging methods for the study of gastronintestinal transit |
CN106573069A (en) * | 2014-08-14 | 2017-04-19 | 梁平 | Methods for killing cancer cells and cellular imaging using magneto-electric nano-particles and external magnetic field |
US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
EP3226819B1 (en) | 2014-11-25 | 2018-10-24 | New Phase Ltd. | Phase-change nanoparticle |
EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
CA3030857C (en) | 2016-07-14 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Methods, apparatuses, and systems for inductive heating of foreign metallic implants |
EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
WO2018195210A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
CA3066742A1 (en) | 2017-06-13 | 2018-12-20 | Houn Simon Hsia | Compositions and methods for enhancing hyperthermia therapy |
GB2567132A (en) * | 2017-08-10 | 2019-04-10 | Hipermag Ltd | Magnetic structures |
WO2019038219A1 (en) * | 2017-08-21 | 2019-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
JP7227237B2 (en) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | Identification of neoantigens using hotspots |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
WO2019120489A1 (en) * | 2017-12-19 | 2019-06-27 | Medical Development Technologies S.A. | Heatable implant device for tumor treatment |
EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
AU2019200986A1 (en) | 2018-02-22 | 2019-09-05 | Robert E. Sandstrom | Magnetic Field Enhancement of Chemotherapy for Tumor Treatment |
US11918315B2 (en) | 2018-05-03 | 2024-03-05 | Pulse Therapeutics, Inc. | Determination of structure and traversal of occlusions using magnetic particles |
CN112538519B (en) * | 2019-09-20 | 2022-09-27 | 华中农业大学 | Method for detecting food-borne pathogenic bacteria by enzymatic low-field nuclear magnetic resonance DNA sensor |
US20220395699A1 (en) * | 2021-06-14 | 2022-12-15 | Novocure Gmbh | Methods of Treating and Preventing Cancer with Alternating Electric Fields, Radioactive Particles, and Systemic Therapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028071A1 (en) * | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US6541039B1 (en) * | 1997-06-20 | 2003-04-01 | Institut Für Neue Materialien Gem. Gmbh | Nanoscale particles having an iron oxide-containing core enveloped by at least two shells |
US20030092029A1 (en) * | 2001-06-06 | 2003-05-15 | Lee Josephson | Magneitc-nanoparticle conjugates and methods of use |
JP2004105722A (en) * | 2002-08-29 | 2004-04-08 | Kansai Tlo Kk | Heating element for thermotherapy and manufacturing method therefor |
US20050249817A1 (en) * | 2004-05-10 | 2005-11-10 | Yousef Haik | Magnetic particle composition for therapeutic hyperthermia |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (en) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4303636A (en) * | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
US4106488A (en) * | 1974-08-20 | 1978-08-15 | Robert Thomas Gordon | Cancer treatment method |
US4119102A (en) * | 1975-07-11 | 1978-10-10 | Leveen Harry H | Radio frequency treatment of tumors while inducing hypotension |
FR2421628A1 (en) * | 1977-04-08 | 1979-11-02 | Cgr Mev | LOCALIZED HEATING DEVICE USING VERY HIGH FREQUENCY ELECTROMAGNETIC WAVES, FOR MEDICAL APPLICATIONS |
US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
US4392040A (en) * | 1981-01-09 | 1983-07-05 | Rand Robert W | Induction heating apparatus for use in causing necrosis of neoplasm |
US4569836A (en) * | 1981-08-27 | 1986-02-11 | Gordon Robert T | Cancer treatment by intracellular hyperthermia |
US4574782A (en) * | 1981-11-16 | 1986-03-11 | Corning Glass Works | Radio frequency-induced hyperthermia for tumor therapy |
US4454234A (en) * | 1981-12-30 | 1984-06-12 | Czerlinski George H | Coated magnetizable microparticles, reversible suspensions thereof, and processes relating thereto |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4622952A (en) * | 1983-01-13 | 1986-11-18 | Gordon Robert T | Cancer treatment method |
EP0330801A1 (en) * | 1983-02-08 | 1989-09-06 | Schering Aktiengesellschaft | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4545368A (en) * | 1983-04-13 | 1985-10-08 | Rand Robert W | Induction heating method for use in causing necrosis of neoplasm |
US4662359A (en) * | 1983-08-12 | 1987-05-05 | Robert T. Gordon | Use of magnetic susceptibility probes in the treatment of cancer |
US4590922A (en) * | 1983-08-19 | 1986-05-27 | Gordon Robert T | Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases |
DE3332843A1 (en) | 1983-09-12 | 1985-04-04 | Broers, Dieter, 8079 Pfalzpaint | DEVICE FOR THE TREATMENT OF LIVING TISSUE WITH ELECTROMAGNETIC WAVES FOR THE PURPOSE OF THE THERAPEUTIC INFLUENCATION IN THE EVENT OF DISEASES |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5087438A (en) * | 1984-07-03 | 1992-02-11 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
US4610241A (en) * | 1984-07-03 | 1986-09-09 | Gordon Robert T | Atherosclerosis treatment method |
US4889120A (en) * | 1984-11-13 | 1989-12-26 | Gordon Robert T | Method for the connection of biological structures |
US4983159A (en) * | 1985-03-25 | 1991-01-08 | Rand Robert W | Inductive heating process for use in causing necrosis of neoplasms at selective frequencies |
US4708718A (en) * | 1985-07-02 | 1987-11-24 | Target Therapeutics | Hyperthermic treatment of tumors |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
DE3719705A1 (en) * | 1986-06-13 | 1987-12-17 | Olympus Optical Co | DEVICE FOR HYPERTHERMAL HEATING THE BODY |
US4813399A (en) * | 1986-07-18 | 1989-03-21 | Gordon Robert T | Process for the treatment of neurological or neuromuscular diseases and development |
US4923437A (en) * | 1986-07-18 | 1990-05-08 | Gordon Robert T | Process for applying a localized magnetic or electric field |
US4996991A (en) * | 1986-07-18 | 1991-03-05 | Gordon Robert T | Method for following the distribution of particles in neurological or neuromuscular tissue and cells |
US4950221A (en) * | 1986-07-18 | 1990-08-21 | Gordon Robert T | Process for affecting molecules in tissue |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5300750A (en) * | 1988-03-16 | 1994-04-05 | Metcal, Inc. | Thermal induction heater |
EP0333381A3 (en) | 1988-03-16 | 1990-07-04 | Metcal Inc. | Thermal seed for treatment of tumors |
US5612019A (en) * | 1988-12-19 | 1997-03-18 | Gordon, Deceased; David | Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles |
US5128147A (en) * | 1989-01-06 | 1992-07-07 | Thermal Developments, Inc. | Heat intensifier and localizer for radiofrequency thermotherapy |
EP0474727B1 (en) * | 1989-05-19 | 1997-07-23 | Genentech, Inc. | Her2 extracellular domain |
US5099756A (en) * | 1989-06-01 | 1992-03-31 | Harry H. Leveen | Radio frequency thermotherapy |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5441746A (en) * | 1989-12-22 | 1995-08-15 | Molecular Bioquest, Inc. | Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production |
US5547682A (en) * | 1989-12-22 | 1996-08-20 | Bioquest, Incorporated | Preparation and use of novel injectable RES avoiding inorganic particles for medical application |
US5935866A (en) * | 1989-12-22 | 1999-08-10 | Binax Nh, Inc. | Preparation of sub 100 A magnetic particles and magnetic molecular switches |
US5203782A (en) * | 1990-04-02 | 1993-04-20 | Gudov Vasily F | Method and apparatus for treating malignant tumors by local hyperpyrexia |
US5067952A (en) * | 1990-04-02 | 1991-11-26 | Gudov Vasily F | Method and apparatus for treating malignant tumors by local hyperpyrexia |
US5834229A (en) * | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
JPH06254168A (en) * | 1991-10-29 | 1994-09-13 | Tanaka Kikinzoku Kogyo Kk | Inside-tissue heating/warming therapy |
DE69225043T2 (en) | 1991-11-20 | 1998-09-03 | Riken Kk | Injectable powder for cancer treatment |
US5413588A (en) * | 1992-03-06 | 1995-05-09 | Urologix, Inc. | Device and method for asymmetrical thermal therapy with helical dipole microwave antenna |
DE69329643T2 (en) * | 1992-04-13 | 2001-03-01 | Dana Farber Cancer Inst Inc | AGAINST CARCINOMA-ASSOCIATED ANTIQUE ANTIBODIES |
US5342757A (en) | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
WO1994021240A2 (en) * | 1993-03-17 | 1994-09-29 | Silica Gel Ges.M.B.H | Superparamagnetic particles, process for producing the same and their use |
US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
US5429583A (en) * | 1993-12-09 | 1995-07-04 | Pegasus Medical Technologies, Inc. | Cobalt palladium seeds for thermal treatment of tumors |
AU2194695A (en) * | 1994-03-28 | 1995-10-17 | Regents Of The University Of California, The | Method for preparing radionuclide-labeled chelating agent-ligand complexes |
US6008203A (en) * | 1995-07-14 | 1999-12-28 | Glycotech Corp. | Methods for treatment of EGF receptor associated cancers |
US5658234A (en) * | 1995-07-24 | 1997-08-19 | J. D. Technologies, Inc. | Method for treating tumors |
US6190870B1 (en) * | 1995-08-28 | 2001-02-20 | Amcell Corporation | Efficient enrichment and detection of disseminated tumor cells |
AUPN568095A0 (en) * | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
DE19612001A1 (en) * | 1996-03-18 | 1997-09-25 | Silica Gel Gmbh Adsorptions Te | Superparamagnetic particles with increased R¶1¶ relaxivity, process for their production and their use |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
AUPN978296A0 (en) * | 1996-05-10 | 1996-05-30 | Gray, Bruce N | Targeted hysteresis hyperthermia as a method for treating cancer |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US5976067A (en) * | 1997-05-28 | 1999-11-02 | Ablation Technologies, Inc. | Combination radioactive and temperature self-regulating thermal seed implant for treating tumors |
US6165440A (en) * | 1997-07-09 | 2000-12-26 | Board Of Regents, The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
WO1999019000A1 (en) | 1997-10-11 | 1999-04-22 | The Research Foundation Of State University Of New York | Controlled size polymeric microspheres with superparamagnetic cores |
AUPP008197A0 (en) | 1997-10-29 | 1997-11-20 | Paragon Medical Limited | Improved targeted hysteresis hyperthermia as a method for treating diseased tissue |
US6242196B1 (en) * | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
US6037129A (en) * | 1998-05-28 | 2000-03-14 | Medical University Of South Carolina | Multi-marker RT-PCR panel for detecting metastatic breast cancer |
US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
US6391026B1 (en) * | 1998-09-18 | 2002-05-21 | Pro Duct Health, Inc. | Methods and systems for treating breast tissue |
US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
AUPP899899A0 (en) | 1999-03-03 | 1999-03-25 | Paragon Medical Limited | Magnetic material |
US6470220B1 (en) * | 1999-03-29 | 2002-10-22 | The Regents Of The University Of California | Diagnosis and treatment of cancers using in vivo magnetic domains |
DE19937493C2 (en) * | 1999-08-07 | 2001-06-07 | Mfh Hyperthermiesysteme Gmbh | Magnetic field applicator for heating magnetic or magnetizable substances or solids in biological tissue |
DE19937492C2 (en) | 1999-08-07 | 2001-08-23 | Mfh Hyperthermiesysteme Gmbh | Magnetic field applicator for heating magnetic or magnetizable substances or solids in biological tissue |
DE19940220B4 (en) * | 1999-08-19 | 2007-05-03 | Magforce Nanotechnologies Ag | Medical preparation for the treatment of osteoarthritis, arthritis and other rheumatic joint diseases |
SE9903185D0 (en) | 1999-09-08 | 1999-09-08 | Europ I Of Science Ab | Therapeutic method and device based on magnetism |
US6514481B1 (en) * | 1999-11-22 | 2003-02-04 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
US6347633B1 (en) * | 2000-01-14 | 2002-02-19 | First Circle Medical, Inc. | Treatment of hepatitis C using hyperthermia |
DE10109105C2 (en) * | 2001-02-24 | 2003-01-09 | Mfh Hyperthermiesysteme Gmbh | Magnetic coil arrangement of a magnetic field applicator for heating magnetic or magnetizable substances or solids in biological tissue |
US7731648B2 (en) | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
DE10156790A1 (en) | 2001-11-19 | 2003-06-18 | Chemagen Biopolymer Technologi | Device and method for treating magnetic particles |
EP1453546A2 (en) | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Treatment of angiogenesis disorders using targeted nanoparticles |
WO2003062198A1 (en) * | 2002-01-24 | 2003-07-31 | Barnes Jewish Hospital | Integrin targeted imaging agents |
DE10331439B3 (en) * | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetic nanoparticles with improved magnetic properties |
FR2855315B1 (en) * | 2003-05-23 | 2005-08-19 | Centre Nat Rech Scient | NEUTRAL-STABLE FERROFLUIDS AND MODIFIED FERROFLUIDS OBTAINED BY MODIFICATION OF THE PARTICLE SURFACE OF THESE FERROFLUIDS |
-
2005
- 2005-11-01 US US11/264,680 patent/US7731648B2/en not_active Expired - Fee Related
-
2006
- 2006-11-01 WO PCT/US2006/060419 patent/WO2007079276A2/en active Application Filing
- 2006-11-01 JP JP2008539149A patent/JP2009513722A/en active Pending
- 2006-11-01 EP EP06849146A patent/EP1945159A4/en not_active Withdrawn
- 2006-11-01 CA CA002628106A patent/CA2628106A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541039B1 (en) * | 1997-06-20 | 2003-04-01 | Institut Für Neue Materialien Gem. Gmbh | Nanoscale particles having an iron oxide-containing core enveloped by at least two shells |
US20030092029A1 (en) * | 2001-06-06 | 2003-05-15 | Lee Josephson | Magneitc-nanoparticle conjugates and methods of use |
US20030028071A1 (en) * | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
JP2004105722A (en) * | 2002-08-29 | 2004-04-08 | Kansai Tlo Kk | Heating element for thermotherapy and manufacturing method therefor |
US20050249817A1 (en) * | 2004-05-10 | 2005-11-10 | Yousef Haik | Magnetic particle composition for therapeutic hyperthermia |
Non-Patent Citations (1)
Title |
---|
See also references of EP1945159A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1945159A2 (en) | 2008-07-23 |
CA2628106A1 (en) | 2007-07-12 |
US7731648B2 (en) | 2010-06-08 |
JP2009513722A (en) | 2009-04-02 |
US20060142749A1 (en) | 2006-06-29 |
WO2007079276A2 (en) | 2007-07-12 |
EP1945159A4 (en) | 2011-12-14 |
US20070112339A9 (en) | 2007-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007079276A3 (en) | Magnetic nanoscale particle compositions, and therapeutic methods related thereto | |
Saeed et al. | Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances | |
WO2005044365A3 (en) | Therapy via targeted delivery of nanoscale particles | |
US10391174B2 (en) | Metallic nanoparticles, preparation and uses thereof | |
JP2010516705A (en) | Susceptor and its use in hyperthermia | |
WO2003022360A3 (en) | Thermotherapy via targeted delivery of nanoscale magnetic particles | |
US20090081122A1 (en) | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant | |
US20100106181A1 (en) | In-situ filter | |
Paul et al. | Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles | |
Grillone et al. | Magnetic nanotransducers in biomedicine | |
Ahmed et al. | Magnetic nanoparticles mediated cancer hyperthermia | |
WO2004071370A3 (en) | Therapy via targeted delivery of nanoscale particles | |
EP1204426B1 (en) | Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases | |
Rahman et al. | Radiosensitization characteristic of superparamagnetic iron oxide nanoparticles in electron beam radiotherapy and brachytherapy | |
Wu et al. | Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art | |
JP2003512336A (en) | Magnetic targeting carrier | |
Moradiya et al. | New way to treat cancer: magnetic nanoparticle based hyperthermia | |
DE2828941C2 (en) | ||
Veeramani et al. | Folate targeted galactomannan coated Iron oxide nanoparticles as a nanocarrier for targeted drug delivery of Capecitabine | |
Ahmed et al. | Advanced nanomaterials for biological applications | |
Subhadarshini et al. | Nanomaterials: Diagnosis and Therapeutic Properties | |
Yazdanpanah et al. | Threatening sarcoma with combinational therapies: Magnetic hyperthermia using nanoparticles | |
Zhang et al. | Recent advances in functionalized ferrite nanoparticles: from fundamentals to magnetic hyperthermia cancer therapy | |
Singla et al. | Green nanomaterials: pioneering approach toward hyperthermia treatment | |
Jain et al. | Magnetic nanoparticles: as a drug targeting carrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2628106 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2008539149 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006849146 Country of ref document: EP |